PEA

Palmitoylethanolamide (PEA) is an endogenous (produced in the body) omega-7 fatty acid amide and is a cannabimimetic compound with unique properties.

Quick facts

  • PEA is an effective and well-tolerated alternative for the treatment of chronic pain

WHAT IS PEA USED FOR?

PEA is known for its ability to reduce chronic and neuropathic pain by modulating the inflammatory response and acting on the endocannabinoid system.

Types of pain that PEA helps manage:

  • Inflammatory pain: arthritis, osteoarthritis, menstrual pain, abdominal and pelvic pain typical of endometriosis, inflammatory bowel disease or multiple sclerosis.
  • Neuropathic pain: diabetic neuropathy, post-chemotherapy neuropathy, low back pain, sciatica or post-herpetic neuralgia.
  • Mixed pain (inflammatory + neuropathic): irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, polymyalgia rheumatica.

DID YOU KNOW THAT...

Virtually everyone can take ZeroDol. There are no conditions, diseases or prescribed medications that contraindicate the use of omega-7 fatty acid PEA.

You can find the PEA in our following product:
Essential line

ZeroDol

$32.42
4.92
(87)
Vitality without pain
View product

Clinical Studies

PEA: Natural pain reliever for everyone

A recent meta-analysis of 11 randomized controlled trials on the effectiveness of PEA supplementation in participants suffering from chronic pain due to a variety of conditions including spinal cord injury, endometriosis, irritable bowel syndrome (IBS), carpal tunnel syndrome, temporomandibular joint arthritis (TMJ), vestibulodynia, burning mouth syndrome, diabetic neuropathy, knee osteoarthritis, dysmenorrhea, and regular use of injectable medications for multiple sclerosis showed that PEA may be an effective and well-tolerated treatment for chronic pain.

Read more Read less
Lang-Illievich K, Klivinyi C, Lasser C, Brenna CTA, Szilagyi IS, Bornemann-Cimenti H. Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials. Nutrients. 2023;

El PEA reduce la intensidad del dolor

El siguiente estudio evaluó los efectos de el PEA en la modulación del dolor en 14 voluntarios sanos mediante un ensayo aleatorizado, doble ciego y cruzado. Los resultados mostraron que el PEA redujo la intensidad del dolor inducido, mejoró la tolerancia al dolor y la modulación condicionada del dolor, sin efectos adversos.

Read more Read less
Klivinyi C, Lang-Illievich K, Rumpold-Seitlinger G, Dorn C, Bornemann-Cimenti H.The Effect of Palmitoylethanolamide on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers-A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial Nutrients. 2022; 4(19):4084.

El PEA en el dolor neuropático

En este estudio de 2022 se evaluó la seguridad y eficacia de el PEA en 70 pacientes con dolor neuropático diabético. Tras 8 semanas de tratamiento, el PEA redujo el dolor, mejoró la calidad del  sueño y disminuyó la inflamación sistémica sin efectos adversos significativos.

Read more Read less
Pickering, E., Steels, E. L., Steadman, K. J., Rao, A., & Vitetta, L. A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain. Inflammopharmacology, 2023; 30(6), 2063–2077.